Ilona Cunningham

Hospital Rd
Concord, NSW 2137, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

Journal: British journal of haematology

Published: September 14, 2025

Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study.

Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study.

Journal: European journal of haematology

Published: June 04, 2025

Completion Rate of Paper-Based and Electronic Patient Reported Outcome Measures in a Multidisciplinary Cancer Survivorship Clinical Setting.

Completion Rate of Paper-Based and Electronic Patient Reported Outcome Measures in a Multidisciplinary Cancer Survivorship Clinical Setting.

Journal: Asia-Pacific journal of clinical oncology

Published: April 16, 2024

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

Journal: Blood

Published: April 12, 2024

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.

Journal: BMJ open

Published: January 18, 2024

First case report of pre-mortem biopsy-proven kidney involvement by necrobiotic xanthogranuloma with monoclonal gammopathy.

First case report of pre-mortem biopsy-proven kidney involvement by necrobiotic xanthogranuloma with monoclonal gammopathy.

Journal: Journal of nephrology

Published: May 11, 2021

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.

Journal: PloS one

Published: February 07, 2019

Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics.

Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics.

Journal: Journal of leukocyte biology

Published: September 19, 2018

Health concerns of cancer survivors after primary anti-cancer treatment.

Health concerns of cancer survivors after primary anti-cancer treatment.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: August 15, 2018

Characteristics of older people in an inpatient haematology unit: A descriptive study.

Characteristics of older people in an inpatient haematology unit: A descriptive study.

Journal: Australasian journal on ageing

Published: July 11, 2018

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Journal: Haematologica

Published: July 10, 2018

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Journal: Haematologica

Published: August 22, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026